logo
Plus   Neg
Share
Email

National Grid 6-month Pre-tax Profit Down 23% - Quick Facts

National Grid PLC (NG.L,NGG) on Thursday reported profit before tax of 404 million pounds for the six months ended 30 September 2019, down 23 percent from 522 million pounds in the same period last year.

Profit to equity shareholders of the parent fell to 393 million pounds from 431 million pounds in the previous-year period. Earnings per share declined to 11.3 pence from 12.7 pence last year, reflecting adverse mark to market remeasurements.

Headline profit before tax was 572 million pounds, compared to 733 million pounds in the prior year. Headline earnings per share were 15.5 pence, compared to 17.8 pence a year ago.

However, underlying earnings per share rose 2 percent to 20.0 pence from 19.7 pence last year, due to a U.S. tax settlement relating to prior periods.

Revenue for the half year declined to 6.29 billion pounds from 6.35 billion pounds in the prior year.

The company announced a new target to achieve net zero for own emissions by 2050.

National Grid said its board of directors has approved an interim dividend of 16.57 pence per share, expected to be paid on 15 January 2020 to shareholders on the register as at 29 November 2018.

This represents 35 percent of the total dividend per share of 47.34 pence in respect of the last financial year to 31 March 2019, and is in line with the Group's dividend policy.

Looking ahead, National Grid expects to deliver asset growth of around 7 percent in the near term, with annual capital investment of around 5 billion pounds.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Toy and board game company Hasbro, Inc. (HAS) reported Monday net earnings attributable to Hasbro for the third quarter of $220.90 million or $1.61 per share, compared to pro forma net earnings of $216.5 million or $1.57 per share in the year-ago period. Excluding items, adjusted earnings for the... Anthony Fauci, senior advisor to President Donald Trump, said the safety and efficacy of COVID-19 vaccine will be known by the end of November or early December. Citing the surging coronavirus cases in the country, Fauci separately said it is a great idea for there to be a uniform mask mandate. The comments come amid drug majors AstraZeneca and Johnson & Johnson announcing that they are resuming.. The U.S. Food and Drug Administration (FDA) has gone ahead with the approval of antiviral drug remdesivir as first treatment for COVID-19, notwithstanding last week's findings by the World Health Organization (WHO) that the drug is not effective for COVID-19 treatment. Thursday, Gilead Sciences announced that the FDA approved remdesivir, sold under the brand name Veklury.
Follow RTT